跳至主要内容
临床试验/NCT03223922
NCT03223922进行中(未招募)不适用

Preservation of Cognition and Neuropsychiatric Functioning With Corpus Callosum Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases: A Pilot Study

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins4 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2017年7月19日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
40
试验地点
4
主要终点
Rate of change of cognitive function

研究概览

简要总结

This is a trial that evaluates the preservation of cognition and neuropsychiatric function following genu-sparing whole brain radiation in patients with brain metastases.

详细描述

Efforts at treating radiation-induced cognitive and neuropsychiatric declines with medications have shown only minimal preliminary cognitive benefit and do not affect quality of life (QOL). Given the structural and functional brain alterations associated with WBRT, preventing rather than treating these radiation-induced changes may produce more favorable outcomes. Innovative radiotherapy techniques can limit the dose of radiation applied to specific brain structures without compromising tumor coverage. In this light, Radiation Therapy Oncology Group (RTOG) recently published a study evaluating the hippocampal avoidance whole brain radiation therapy (WBRT) in patients with brain metastases. They suggest potential preservation of cognitive function with this approach with no perceived detriment in survival. This concept is currently undergoing investigation in a definitive randomized controlled study (NRG-CC003) in patients receiving prophylactic cranial irradiation for small cell lung cancer. However, no other studies to date have prospectively evaluated avoidance of other particularly sensitive brain regions.

One brain region that has received little attention in the radiotherapy literature is the corpus callosum. The genu of the corpus callosum contains thin, densely packed neural fibers that primarily connect the prefrontal association areas and the anterior inferior parietal regions of the brain. Damage or thinning of the genu is associated with reduced functioning on tests of executive functioning, attention, working memory, processing speed, verbal fluency and memory in a variety of healthy and patient groups including aging, cerebral small vessel disease, traumatic brain injury, multiple sclerosis , human immunodeficiency virus, mild cognitive impairment secondary to Parkinson's disease, and euthymic bipolar disorder. The limited existing data in adults receiving WBRT for brain metastases suggest that they also perceive progressive declines in motivation following treatment. Given its apparent involvement in a wide range of cognitive processes, the genu of the corpus callosum is an excellent candidate for sparing in WBRT. This relatively small area has the potential to preserve cognitive functioning across several domains if guarded from the damaging effects of radiation. In this study patients will receive the standard whole brain radiation dose of 3000 centigray (cGy) in 10 fractions, but intensity modulated radiation therapy will be utilized to limit radiation dose to the genu of the corpus callosum. Patients will undergo cognitive testing at baseline and at 4-, 6- and 12-months following completion of brain radiation to evaluate the study hypothesis.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 100 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Histologic proof or unequivocal cytologic proof solid tumor malignancy. This may be obtained from either the primary or any metastatic site
  • Mini Mental State Examination (MMSE) ≥24
  • Age≥ 18 years
  • Karnofsky Performance Status (KPS) ≥70
  • Patient does not have metastases to the genu
  • Patient must be scheduled to undergo treatment with whole brain radiation therapy (WBRT) to manage the brain metastases
  • Patients of childbearing potential (male or female) must practice adequate contraception due to possible harmful effects of radiation therapy on an unborn child
  • Patient must have the ability to understand and the willingness to sign a written informed consent document
  • All patients must be informed of the investigational nature of this study and must be given written informed consent in accordance with institutional and federal guidelines
  • Patient must have a minimal life expectancy of at least 6 months
  • Patients receiving prior stereostatic radiosurgery (SRS) for brain metastases are eligible

排除标准

  • Prior WBRT
  • Patient has brain metastases in the genu
  • Patients must not have a serious medical or psychiatric illness that would, in the opinion of the treating physician prevent informed consent or completion of protocol treatment, and/or follow-up visits.
  • Non-native English speakers will be excluded since patients often lose their faculty with the language they acquired second before their native language is affected in the context of cognitive decline. This could adversely affect performance on verbal cognitive tasks.
  • Patients with absolute contraindication to MRI imaging are not eligible for the study

研究组 & 干预措施

Corpus Callosum Genu-Sparing Whole Brain Radiation Therapy

Experimental

Genu-sparing whole brain radiation therapy (GS-WBRT) 30 Gy in 3 Gy per fraction

干预措施: whole brain radiation therapy (Radiation)

结局指标

主要结局

Rate of change of cognitive function

时间窗: 4 months

Evaluate changes in cognition from baseline to 4 months following genu-sparing whole brain radiation therapy (GS-WBRT)

次要结局

  • Rate of change in other frontally-mediated functions(4, 6 and 12 months)
  • Rate of change of white matter microstructure(4, 6 and 12 months)
  • Time to brain metastasis(4, 6 and 12 months)
  • Rate of change in QoL(4, 6 and 12 months)
  • Rate of change of cognition(4, 6 and 12 months)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (4)

Loading locations...

相似试验

已完成
不适用
Outcomes Following Neuropsychological Intervention in Acquired Brain Injury Outpatients With Executive DysfunctionAcquired Brain Injury
NCT01992055University of Manitoba18
招募中
不适用
Cognitive Status After Removal of Skull Base MeningiomaSkull Base MeningiomaFrontal MeningiomaTemporal MeningiomaCognitive ImpairmentCognitive DeclinePost-Surgical CognitionMeningioma
NCT04635657Ohio State University50
已完成
不适用
Natural History of Brain Function, Quality of Life, and Seizure Control in Patients With Brain Tumor Who Have Undergone SurgeryAdult Diffuse AstrocytomaAdult Mixed GliomaAdult OligodendrogliomaCognitive/Functional EffectsNeurotoxicityPsychosocial Effects of Cancer and Its TreatmentSeizure
NCT01417507Radiation Therapy Oncology Group82
已完成
不适用
Neuropsychological and Behavioral Testing in Younger Patients With CancerChildhood Malignant Neoplasm
NCT00772200Children's Oncology Group1,200
已完成
不适用
Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving ChemotherapyCognitive Side Effects of Cancer TherapyMalignant Ovarian Epithelial TumorOvarian Brenner TumorOvarian CarcinosarcomaOvarian ChoriocarcinomaOvarian Clear Cell CystadenocarcinomaOvarian DysgerminomaOvarian Embryonal CarcinomaOvarian Endometrioid AdenocarcinomaOvarian Mixed Germ Cell TumorOvarian Mucinous CystadenocarcinomaOvarian PolyembryomaOvarian SarcomaOvarian Seromucinous CarcinomaOvarian Serous CystadenocarcinomaOvarian Yolk Sac TumorStage I Ovarian CancerStage IA Fallopian Tube CancerStage IA Ovarian CancerStage IA Ovarian Germ Cell TumorStage IB Fallopian Tube CancerStage IB Ovarian CancerStage IB Ovarian Germ Cell TumorStage IC Fallopian Tube CancerStage IC Ovarian CancerStage IC Ovarian Germ Cell TumorStage II Ovarian CancerStage IIA Fallopian Tube CancerStage IIA Ovarian CancerStage IIA Ovarian Germ Cell TumorStage IIB Fallopian Tube CancerStage IIB Ovarian CancerStage IIB Ovarian Germ Cell TumorStage IIC Fallopian Tube CancerStage IIC Ovarian CancerStage IIC Ovarian Germ Cell TumorStage IIIA Fallopian Tube CancerStage IIIA Ovarian CancerStage IIIA Ovarian Germ Cell TumorStage IIIA Primary Peritoneal CancerStage IIIB Fallopian Tube CancerStage IIIB Ovarian CancerStage IIIB Ovarian Germ Cell TumorStage IIIB Primary Peritoneal CancerStage IIIC Fallopian Tube CancerStage IIIC Ovarian CancerStage IIIC Ovarian Germ Cell TumorStage IIIC Primary Peritoneal CancerStage IV Fallopian Tube CancerStage IV Ovarian CancerStage IV Ovarian Germ Cell TumorStage IV Primary Peritoneal CancerUndifferentiated Ovarian CarcinomaOvarian Teratoma
NCT01080521Gynecologic Oncology Group247